A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Trial Profile

A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Capmatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 May 2016 Status changed from not yet recruiting to recruiting.
    • 03 May 2016 Planned initiation date changed from 1 Apr 2016 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top